OQS
RVNC

Occudo Quantitative Strategies’s Revance Therapeutics, Inc. RVNC Stock Holding History

Occudo Quantitative Strategies’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-45,324
Closed -$398K – 1071
2023
Q4 		$398K Buy
+45,324
New +$371K 0.05% 457
2023
Q2 		– Sell
-21,918
Closed -$706K – 1343
2023
Q1 		$706K Sell
21,918
-18,834
-46% -$587K 0.06% 414
2022
Q4 		$752K Buy
40,752
+24,278
+147% +$555K 0.09% 373
2022
Q3 		$445K Sell
16,474
-27,295
-62% -$554K 0.03% 704
2022
Q2 		$605K Buy
+43,769
New +$674K 0.05% 554

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Occudo Quantitative Strategies's RVNC Position: Q1 2024 in Review

Occudo Quantitative Strategies sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2024, closing a stake of 45,324 shares — an estimated $398K sold.

Occudo Quantitative Strategies first reported a position in RVNC in Q2 2022 and held it in 5 quarters. The position peaked at $752K in Q4 2022. 188 funds tracked by Wall St. Rank hold RVNC as of Q1 2024.

  • Occudo Quantitative Strategies reported no remaining Revance Therapeutics, Inc. position as of Q1 2024 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 45,324 Revance Therapeutics, Inc. shares in Q1 2024, an estimated $398K.
  • Occudo Quantitative Strategies first reported a position in Revance Therapeutics, Inc. in Q2 2022 and held it in 5 quarters.
  • Occudo Quantitative Strategies's Revance Therapeutics, Inc. position peaked at $752K in Q4 2022.
  • 188 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2024.

Based on Occudo Quantitative Strategies's 13F filing for Q1 2024, filed 15 May 2024.